[CAS NO. 1446182-94-0] CUDC-427
PRODUCTS SPECIFICATIONS [1446182-94-0]
DESCRIPTION [1446182-94-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 564.70 |
| Molecular Formula | C29H36N6O4S |
| SMILES | O=C([C@H](CCC1)N1C([C@H](C2CCCCC2)NC([C@H](C)NC)=O)=O)NC3=C(C4=CC=CC=C4)N=C(C5=NC=CO5)S3 |
2 Publications Citing Use of MCE
Summary
CUDC-427 is a potent second-generation pan-selective IAP antagonist, used for treatment of various cancers.
In Vitro
GDC-0917 (0.1 nM-10 μM) induces reduction of cIAP1 levels in PBMCs in a concentration-dependent manner showing greater than 80% inhibition at concentrations greater than 0.1 µM (56.5 ng/mL) [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
GDC-0917 (0.08-16.3 mg/kg) exhibits antitumor activity in a dose dependent manner in the MDA-MB-231-X1.1 Breast Cancer Xenograft, and GDC-0917 is well tolerated, with all dose groups experiencing a <11% decrease in mean body weight. GDC-0917 has low to moderate clearance in the mouse (12.0 mL/min/kg), rat (27.0 mL/min/kg), and dog (15.3 mL/min/kg), and high clearance in the monkey (67.6 mL/min/kg). Oral bioavailability is lowest in monkeys compared with other species [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01226277 | Genentech, Inc. |
Solid Cancers
|
October 2010 | Phase 1 |
| NCT01908413 | Curis, Inc. |
Lymphoma
|
July 2013 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 88.54 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.7709 mL | 8.8543 mL | 17.7085 mL |
| 5 mM | 0.3542 mL | 1.7709 mL | 3.5417 mL |
| 10 mM | 0.1771 mL | 0.8854 mL | 1.7709 mL |
-
1.